acetyl-CoA carboxylase 1/2 inhibitors (Pfizer)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameacetyl-CoA carboxylase 1/2 inhibitors (Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAcetyl-CoA carboxylase 2 inhibitorsAcetyl-CoA carboxylase 1 inhibitors
TargetsAcetyl-CoA carboxylase 2Acetyl-CoA carboxylase 1
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A